ICD-10 G43.909: Migraine Coding and Billing Guide

Migraine is a neurological condition affecting approximately 39 million Americans, with significant economic impact from lost productivity, emergency department visits, and treatment costs. ICD-10 code G43.909 represents an unspecified migraine that is not intractable, but this broad classification limits treatment options and authorization approvals for patients who need them most.

Moving Beyond G43.909

G43.909 tells payers almost nothing about the patient’s migraine pattern. The ICD-10 migraine classification system distinguishes between migraine without aura (G43.0x), migraine with aura (G43.1x), hemiplegic migraine (G43.4x), chronic migraine (G43.7x), and several other subtypes. Each category has variants for intractability and status migrainosus.

For billing purposes, the distinction between episodic and chronic migraine (G43.7x) is the most consequential. Chronic migraine, defined as 15 or more headache days per month for at least 3 months, unlocks treatment options that are not available for episodic migraine codes. Botox injections, certain CGRP inhibitors, and some intensive outpatient programs require a chronic migraine code for authorization.

Headache Diary as a Billing Tool

A headache diary serves dual purposes in migraine management. Clinically, it tracks attack frequency, triggers, and treatment response. From a billing perspective, it provides the documentation foundation for diagnosis specificity and treatment authorization.

The diary should record the date and duration of each headache, pain severity on a standardized scale, associated symptoms (aura, nausea, photophobia), acute medications used and their effectiveness, and impact on daily activities. Three months of diary data converts G43.909 to a specific code with documented frequency patterns.

Payers reviewing prior authorization requests for migraine medications look specifically for diary data. A request stating “patient reports frequent migraines” without supporting diary documentation is weaker than one that includes “headache diary from January through March 2026 shows 18 headache days per month, with 12 meeting migraine criteria, despite daily topiramate 100mg.”

CGRP Inhibitor Authorization Pathway

Calcitonin gene-related peptide (CGRP) inhibitors represent the first medication class specifically designed for migraine prevention. Erenumab (Aimovig), fremanezumab (Ajovy), galcanezumab (Emgality), and eptinezumab (Vyepti) each cost $6,000 to $12,000 per year, making prior authorization inevitable.

The standard authorization pathway requires a migraine diagnosis with documented frequency (typically 4+ migraine days per month for episodic or 15+ headache days for chronic), failure of 2 to 3 classes of oral preventive medications, and a headache diary demonstrating the migraine burden. Most payers specify which medication classes count as adequate trials. Commonly accepted categories include beta-blockers (propranolol, metoprolol), anticonvulsants (topiramate, valproate), antidepressants (amitriptyline, venlafaxine), and calcium channel blockers (verapamil).

Each failed medication trial must document the specific drug, dose achieved, duration of treatment (typically at least 2 months at therapeutic dose), and reason for discontinuation (lack of efficacy, adverse effects, or contraindication). Missing any of these elements is the most common reason for CGRP inhibitor denial on first submission.

Botox for Chronic Migraine: Coding and Authorization

OnabotulinumtoxinA (Botox) injection for chronic migraine uses CPT 64615 for the injection procedure and J0585 for the medication. The FDA-approved protocol involves 155 units injected across 31 sites in 7 head and neck muscle groups, repeated every 12 weeks.

Authorization requires a chronic migraine diagnosis (G43.7x, not G43.909), headache diary data showing 15 or more headache days per month for at least 3 consecutive months, and documentation of failed oral preventive therapy. Some payers require failure of 2 oral preventives, while others require 3.

Billing for Botox injections must capture both the procedure code and the drug units. For 155 units, report J0585 x 155 (or as directed by the specific payer’s unit definition). The procedure documentation should list each injection site, the units administered per site, and any deviation from the standard protocol with clinical justification.

Emergency Department Migraine Coding

Migraine is a leading cause of emergency department visits, and ED coding has specific requirements. An intractable migraine (one that does not respond to standard treatment) uses the intractable variant of the appropriate migraine code. Status migrainosus (a migraine lasting more than 72 hours) adds the status migrainosus designation.

ED visits for migraine should document the onset, duration, treatments attempted before arrival, and the clinical assessment of severity. If the provider determines the migraine is intractable, that terminology should appear in the note to support the intractable code variant. Undercoding intractable migraines as simple migraine episodes does not reflect the true clinical severity and undersupports the E/M level and treatment administered.

Quality Measures and Migraine Management

Migraine management intersects with several quality reporting measures. Appropriate use of acute migraine medications, avoidance of opioid prescribing for migraine, and follow-up after ED visits for migraine are all tracked in various quality programs.

Practices that use specific migraine codes rather than G43.909 generate more accurate quality data and demonstrate better clinical care patterns. Quality measure performance increasingly affects reimbursement through MIPS adjustments and value-based contract terms, making accurate migraine coding a financial priority for neurology and headache medicine practices.